The study assessed changes in retinal structure and visual function before and after intravitreal pegcetacoplan initiation. A ...

Thank you, Eva, and thank you all for joining us this morning. Before turning to our fourth quarter results, I would like to ...

Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) ...

At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical ...

Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...

Professor Souied is a renowned ophthalmologist and international expert in AMD (Age-related Macular Degeneration)  He will guide the scientific focus of SeaBeLife’s ophthalmological program, the only ...

-- The unmet need and current treatment landscape for GA -- The mechanism of disease and role of C1q -- Vonaprument, Annexon's neuroprotective C1q inhibitor with the potential to be the first targeted ...

Market expansion in med derm cross over: Almirall’s Seysara (sarecycline) won NMPA approval for moderate to severe acne (≥9 years), with China commercial launch targeted for 2026 – relevant to ...

Learn more about whether Apellis Pharmaceuticals, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

BOSTON, Feb. 3, 2026 /PRNewswire/ -- ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX), a ...